| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 04/30/2013 | US8431598 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 04/30/2013 | US8431574 Heterocyclic inhibitors of MEK and methods of use thereof |
| 04/30/2013 | US8431380 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/30/2013 | US8431354 Bacterial pheromones and uses therefor |
| 04/30/2013 | US8431350 Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide |
| 04/30/2013 | US8431124 Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP) |
| 04/30/2013 | CA2540869C Spill resistant formulations containing clays |
| 04/30/2013 | CA2517256C Aminoheteroaryl compounds as protein kinase inhibitors |
| 04/25/2013 | US20130102555 Method of treating diabetes |
| 04/25/2013 | US20130101616 Compositions of botanical extracts for cancer therapy |
| 04/24/2013 | CN1869061B Peptidomimetic protease inhibitors |
| 04/24/2013 | CN103054901A Dialysates and methods and systems related thereto |
| 04/24/2013 | CN101265226B Compounds and methods for delivery of prostacyclin analogs |
| 04/23/2013 | US8425933 Abuse-resistant oral dosage forms and method of use thereof |
| 04/23/2013 | CA2504818C Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 04/18/2013 | US20130096137 Treating Sexual Desire Disorders with Flibanserin |
| 04/18/2013 | US20130096128 Pyrazole compounds useful as protein kinase inhibitors |
| 04/18/2013 | US20130095195 Jucara and acai fruit based dietary supplements |
| 04/18/2013 | US20130095156 Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
| 04/18/2013 | US20130095034 Anti-CD74 Immunoconjugates and Methods |
| 04/17/2013 | CN103040732A Immunoglobulin formulation and method of preparation thereof |
| 04/17/2013 | CN101371923B BAFF receptor (BCMA), an immunoregulatory agent |
| 04/16/2013 | US8420799 Therapeutic compositions |
| 04/16/2013 | CA2547569C Recombinant factor viii having increased specific activity |
| 04/09/2013 | CA2537782C Water-soluble polyaminoamides as sunscreen agents |
| 04/09/2013 | CA2361658C T helper cell epitopes |
| 04/03/2013 | CN103006592A Pharmaceutical compositions for glucocorticoid replacement therapy |
| 04/02/2013 | US8410169 synergistic mixture with drug therapy for cardiovascular disorders; respiratory system disorders |
| 04/02/2013 | US8410131 Cancer treatment |
| 04/02/2013 | CA2695720C Method of producing epothilone b by culturing sorangium cellulosum in a medium comprising propionic acid |
| 04/02/2013 | CA2514327C Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
| 03/28/2013 | US20130079284 Treatment of t-cell mediated diseases |
| 03/28/2013 | US20130078241 Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same |
| 03/27/2013 | CN1913920B Influenza immunogen and vaccine |
| 03/27/2013 | CN1370083B Ninovasive genetic immnization, expression products therefrom, and uses thereof |
| 03/27/2013 | CN101912615B Cladribine formulations for improved oral and transmucosal delivery |
| 03/26/2013 | US8404820 Human monoclonal antibodies against Bacillus anthracis protective antigen |
| 03/26/2013 | CA2536454C Ocular drug delivery device |
| 03/21/2013 | US20130072684 Treatment of t-cell mediated diseases |
| 03/21/2013 | US20130072569 Retinoid replacements and opsin agonists and methods for the use thereof |
| 03/21/2013 | US20130072568 Retinoid replacements and opsin agonists and methods for the use thereof |
| 03/21/2013 | US20130072503 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
| 03/21/2013 | US20130072443 Stabilized mutant opsin proteins |
| 03/21/2013 | US20130071448 Treatment of t-cell mediated diseases |
| 03/21/2013 | US20130071436 Treatment of t-cell mediated diseases |
| 03/21/2013 | US20130071386 Immunoglobulin Formulation and Method of Preparation Thereof |
| 03/20/2013 | CN101242850B Composition, function and use of xanthoceras sorbifolia extract and compound isolated from same, method for preparing same |
| 03/19/2013 | US8399515 Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements |
| 03/19/2013 | US8399469 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 03/19/2013 | CA2536086C Inhibition of dr3 in the treatment of allergic lung inflammation |
| 03/19/2013 | CA2534313C Formulations containing an immune response modifier |
| 03/19/2013 | CA2514092C Novel cocrystallization of hydrochloric acid salt of an active agent |
| 03/19/2013 | CA2513251C Cancer therapy sensitizer |
| 03/19/2013 | CA2499278C Method of preparing dry powder inhalation compositions |
| 03/19/2013 | CA2453260C Vaccine formulation potentiated by the combination of a dna and an antigen |
| 03/14/2013 | US20130065963 Histone Deacetylase Inhibitors and Methods of Use Thereof |
| 03/14/2013 | US20130065917 Salt of naphthyridine carboxylic acid derivative |
| 03/14/2013 | US20130065839 Treatment of t-cell mediated diseases |
| 03/13/2013 | CN101721402B Treating bone-related disorders with selective androgen receptor modulators |
| 03/13/2013 | CN101633636B Peptidomimetic protease inhibitors |
| 03/13/2013 | CN101434572B Prodrugs of GABA analogs, compositions and uses thereof |
| 03/12/2013 | US8394406 Once daily formulations of tetracyclines |
| 03/12/2013 | US8394405 Once daily formulations of tetracyclines |
| 03/12/2013 | CA2537029C Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| 03/12/2013 | CA2531661C Histone deacetylase inhibitors and methods of use thereof |
| 03/12/2013 | CA2517077C Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 03/12/2013 | CA2510455C Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 03/12/2013 | CA2503383C Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 03/12/2013 | CA2490189C Method, routines and system for identification of imprints on dosage forms |
| 03/07/2013 | US20130059877 Treatment of solid tumors with rapamycin derivatives |
| 03/07/2013 | US20130059810 Pharmaceutical compositions comprising forms of 5-azacytidine |
| 03/07/2013 | US20130059809 Pharmaceutical compositions comprising forms of 5-azacytidine |
| 03/07/2013 | US20130059771 Function and Regulation of Angiopoietin-3/Angiopoietin-4 |
| 03/07/2013 | US20130059752 Compositions and methods for the treatment of immune related diseases |
| 03/07/2013 | US20130058942 Human beta-adrenergic receptor kinase polypeptide and methods |
| 03/07/2013 | US20130058893 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 03/05/2013 | US8389680 Treatment of Aspergillus infections with alpha thymosin peptides |
| 03/05/2013 | US8389540 Polymorphic solvates of naltrexone with ethanol, benzyl alcohol, dimethylformamide, methanol, dichloromethane, acetone and hexane; sustained release formulations |
| 03/05/2013 | US8389473 Treatment of cardiac arrhythmias |
| 03/05/2013 | US8388601 Viscoelastic solution or gel formulation, and methods of treating a body site with the same |
| 02/28/2013 | US20130052220 Yeast-hiv antigen compositions and methods of using the same |
| 02/28/2013 | US20130048532 Nosebleed lip pack |
| 02/27/2013 | EP2561887A2 Cancer therapy sensitizer |
| 02/27/2013 | CN102943067A Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 02/26/2013 | US8383126 Bacterial pheromones and uses thereof |
| 02/26/2013 | CA2523426C Aza spiro alkane derivatives as inhibitors of metalloproteases |
| 02/21/2013 | US20130045216 Method for Treating Amyloid Disease |
| 02/21/2013 | US20130043612 Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms |
| 02/20/2013 | CN102935069A Method for the preparation of controlled release formulations |
| 02/19/2013 | CA2532798C Azepine derivatives as pharmaceutical agents |
| 02/19/2013 | CA2520400C Treatment of aspergillus infections with thymosin alpha 1 |
| 02/19/2013 | CA2469092C Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als) |
| 02/13/2013 | EP2557164A1 Induced activation in dendritic cells |
| 02/13/2013 | CN101245043B Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| 02/12/2013 | US8372449 Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering pruified quinic acid and/or carboxy alkyl ester |
| 02/12/2013 | US8372448 Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester |
| 02/12/2013 | US8372388 Method for preparing a stable TNF-α vaccine |
| 02/12/2013 | CA2529817C Novel antibacterial agents |
| 02/07/2013 | US20130035328 Antiviral compounds and methods |
| 02/06/2013 | CN102210717B Compositions comprising Lactobacillus plantarum strains in combination with tannin and new Lactobacillus plantarum strains |